+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

8-OH-DPAT, a 5-HT-1A agonist and ritanserin, a 5-HT-2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release



8-OH-DPAT, a 5-HT-1A agonist and ritanserin, a 5-HT-2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release



Psychopharmacology. 131(1): 57-63



In this study, both catalepsy and changes in extracellular levels of striatal dopamine (DA) and dihydroxyphenyl acetic acid (DOPAC) induced by the typical neuroleptic haloperidol (HAL) were simultaneously assessed, using intracerebral microdialysis in freely moving rats, in the presence of either the 5-HT-1A agonist 8-OH-DPAT or the 5-HT-2A/C antagonist ritanserin. HAL (1 mg/kg, SC) elicited a strong cataleptic state, reaching its maximal intensity (about 240 s) 2 h after the drug administration. This effect was paralleled by a long-lasting enhancement of striatal DA and DOPAC extracellular levels, reaching 230 and 350% of basal values, respectively. 8-OH-DPAT (0.1 mg/kg, SC) given 2.5 h after, and ritanserin (0.63 and 1.25 mg/kg, IP), given 15 min prior to HAL, significantly reduced the neuroleptic-induced catalepsy. However, both 5-HT agents failed to modify basal DA and DOPAC striatal outflow as well as the stimulatory effect of HAL on these parameters. It can thus be concluded that the anti-cataleptic effect of these compounds is not related to an alteration of DA release within the striatum.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008018454

Download citation: RISBibTeXText

PMID: 9181636

DOI: 10.1007/s002130050265


Related references

The alpha2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: Role of serotonergic mechanisms. Neuropsychopharmacology 28(5): 872-879, 2003

Brain tyrosine depletion attenuates haloperidol-induced striatal dopamine release in vivo and augments haloperidol-induced catalepsy in the rat. Psychopharmacology 172(1): 100-107, 2004

8-OH-DPAT (5-HT1A agonist) Attenuates 6-Hydroxy- dopamine-induced catalepsy and Modulates Inflammatory Cytokines in Rats. Iranian Journal of Basic Medical Sciences 16(12): 1270-1275, 2013

Effects of aminooxy acetic acid and baclofen on the catalepsy and on the increase of meso limbic and striatal dopamine turnover induced by haloperidol in rats. Acta Pharmacologica et Toxicologica 39(3): 393-400, 1976

Attenuation of haloperidol-induced dopamine release by 8-OH DPAT in the rat A correlate for the anticataleptic effects of 8-OH-DPAT?. Society for Neuroscience Abstracts 19(1-3): 1384, 1993

Effect of acute morphine or haloperidol administration on catalepsy and striatal dopamine turnover in rats chronically treated with morphine or haloperidol. Pharmacologist: 259, 1973

TYROSINE DEPLETION AUGMENTS HALOPERIDOL - INDUCED CATALEPSY AND ATTENUATES HALOPERIDOL - INDUCED DOPAMINE RELEASE IN THE STRIATUM OF THE RAT As MEASURED BY in vivo MICRODIALYSIS. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 536 3, 2002

Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. Journal of Neural Transmission. General Section 89(1-2): 49-59, 1992

Acute versus chronic haloperidol: Relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine release. Brain Research 634(1): 20-30, 1994

Ritanserin, a 5-HT2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons. Journal of Pharmacology and Experimental Therapeutics 274(2): 735-740, 1995

Antagonism by 8-hydroxy-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. Journal of Neural Transmission General Section 89(1-2): 49-59, 1992

Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity. Psychopharmacology 90(1): 54-57, 1986

Conditional tolerance to haloperidol-induced catalepsy: striatal dopamine receptor supersensitivity is a possible explanation. Psychopharmacology 95(1): 142-145, 1988

Catalepsy, brain dopamine metabolism and the interaction between haloperidol and 8-OH-DPAT. British Journal of Pharmacology 114(PROC Suppl. ): 121P, 1994

Effect of W-7 or dantrolene on haloperidol-induced changes in evoked dopamine release from striatal slices of rats. Neurosciences 21(Suppl. 2): P101-P104, 1995